PE20191707A1 - Composicion para la medicion, prevencion o alivio del envejecimiento de la piel usando hapln1 - Google Patents

Composicion para la medicion, prevencion o alivio del envejecimiento de la piel usando hapln1

Info

Publication number
PE20191707A1
PE20191707A1 PE2019001813A PE2019001813A PE20191707A1 PE 20191707 A1 PE20191707 A1 PE 20191707A1 PE 2019001813 A PE2019001813 A PE 2019001813A PE 2019001813 A PE2019001813 A PE 2019001813A PE 20191707 A1 PE20191707 A1 PE 20191707A1
Authority
PE
Peru
Prior art keywords
hapln1
skin aging
agent
level
composition
Prior art date
Application number
PE2019001813A
Other languages
English (en)
Inventor
Dae Kyong Kim
Zhicheng Fu
Moon Jung Back
Original Assignee
Haplnscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haplnscience Inc filed Critical Haplnscience Inc
Publication of PE20191707A1 publication Critical patent/PE20191707A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/148—Screening for cosmetic compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

REFERIDO A UNA COMPOSICION DE BIOMARCADOR PARA MEDIR EL ENVEJECIMIENTO DE LA PIEL, EL CUAL COMPRENDE UN AGENTE PARA DETECTAR PROTEINA HAPLN1 O GEN HAPLN1 DE UNA MUESTRA BIOLOGICA, EN DONDE DICHO AGENTE ES UN ANTICUERPO, UN ARN ANTISENTIDO, UN APTAMERO O UN COMPUESTO. TAMBIEN SE REFIERE A UN KIT PARA MEDIR EL ENVEJECIMIENTO DE LA PIEL Y UN METODO DE BUSQUEDA DE UN AGENTE DE ALIVIO DEL ENVEJECIMIENTO DE LA PIEL, QUE COMPRENDE INCUBAR UNA MUESTRA BIOLOGICA CON UN COMPUESTO, DETECTAR UN NIVEL DE EXPRESION DE PROTEINA O GEN HAPLN1 DE LA MUESTRA, Y COMPARAR SU NIVEL DE EXPRESION CON UN NIVEL DE LA MISMA PROTEINA O GEN EN UN CONTROL NORMAL NO INCUBADO CON EL COMPUESTO
PE2019001813A 2017-03-06 2017-03-06 Composicion para la medicion, prevencion o alivio del envejecimiento de la piel usando hapln1 PE20191707A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2017/002395 WO2018164290A1 (ko) 2017-03-06 2017-03-06 Hapln1을 이용한 피부 노화 측정 또는 예방 또는 개선용 조성물

Publications (1)

Publication Number Publication Date
PE20191707A1 true PE20191707A1 (es) 2019-11-28

Family

ID=63448272

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001813A PE20191707A1 (es) 2017-03-06 2017-03-06 Composicion para la medicion, prevencion o alivio del envejecimiento de la piel usando hapln1

Country Status (16)

Country Link
US (1) US11202749B2 (es)
EP (1) EP3594685A4 (es)
JP (1) JP2020514739A (es)
CN (1) CN110603448A (es)
AU (1) AU2017403257B2 (es)
BR (1) BR112019018469A2 (es)
CA (1) CA3055168C (es)
CO (1) CO2019009796A2 (es)
IL (1) IL269126B (es)
MX (1) MX2019010533A (es)
NZ (1) NZ756946A (es)
PE (1) PE20191707A1 (es)
RU (1) RU2750486C2 (es)
SG (1) SG11201908160VA (es)
WO (1) WO2018164290A1 (es)
ZA (1) ZA201905864B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20230436A1 (es) * 2019-02-28 2023-03-08 Haplnscience Inc Composicion para prevenir, mejorar o tratar enfermedades o sintomas relacionados con el cartilago que comprende hapln1
KR102166453B1 (ko) * 2020-02-03 2020-10-15 중앙대학교 산학협력단 Hapln1을 포함하는 폐질환 예방 또는 치료용 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6156114A (ja) * 1984-08-27 1986-03-20 Kanebo Ltd 皮膚老化防止用化粧料
DE10100121A1 (de) * 2001-01-03 2002-08-01 Henkel Kgaa Verfahren zur Bestimmung des Hautstreß oder der Hautalterung in vitro
GB0422525D0 (en) * 2004-10-11 2004-11-10 Luebcke Peter Dermatological compositions and methods
US20090220488A1 (en) * 2005-08-31 2009-09-03 Humphrey Gardner Evaluating and treating scleroderma
US7908090B2 (en) * 2005-11-30 2011-03-15 The Board Of Trustees Of The Leland Stanford Junior University Signatures for human aging
WO2008013934A2 (en) * 2006-07-27 2008-01-31 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
PL2132562T3 (pl) * 2007-04-06 2012-06-29 Genzyme Corp Sposób oceniania komórek i hodowli komórkowych
KR100921971B1 (ko) * 2007-10-24 2009-10-15 한국과학기술연구원 블루밍샐리 추출물을 유효성분으로 함유하는 조성물
US20140163118A1 (en) * 2011-05-03 2014-06-12 Dermachip Inc. Expression Signatures of Genes and Gene Networks Associated with Skin Aging
WO2012156420A1 (en) * 2011-05-17 2012-11-22 Chanel Parfums Beaute Large, hs6st2 or st8sia1 activators for preventing and/or attenuating skin ageing and/or hydrating skin
DE102011085497A1 (de) * 2011-10-31 2013-05-02 Evonik Industries Ag Kosmetische Formulierung
WO2013129456A1 (ja) * 2012-02-29 2013-09-06 ロート製薬株式会社 線維芽細胞増殖促進能を有する組成物
KR101784766B1 (ko) * 2012-03-16 2017-10-13 서울대학교산학협력단 신규한 ｔｒｐｖ１ 억제 펩티드 및 이를 함유하는 피부노화 방지 또는 주름 개선용 조성물
EP2845910A4 (en) * 2012-05-02 2015-11-25 Mitsubishi Rayon Co PROBE OR PROBE TO EVALUATE THE INFLUENCE OF ULTRAVIOLET RADIATION ON SKIN AND NUCLEIC ACID MICRO ARRAYS
EP3027058B1 (en) * 2013-07-31 2020-07-15 Incredible Foods, Inc. Encapsulated functional food compositions
GB201505520D0 (en) * 2015-03-31 2015-05-13 Univ Lancaster Composition
KR101897340B1 (ko) * 2015-09-09 2018-09-13 중앙대학교 산학협력단 Hapln1을 이용한 피부 노화 측정 또는 예방 또는 개선용 조성물

Also Published As

Publication number Publication date
CA3055168C (en) 2022-09-06
CA3055168A1 (en) 2018-09-13
AU2017403257B2 (en) 2021-09-30
MX2019010533A (es) 2019-12-19
US20200000700A1 (en) 2020-01-02
SG11201908160VA (en) 2019-10-30
EP3594685A1 (en) 2020-01-15
EP3594685A4 (en) 2020-11-18
ZA201905864B (en) 2021-10-27
CN110603448A (zh) 2019-12-20
NZ756946A (en) 2022-07-01
WO2018164290A1 (ko) 2018-09-13
IL269126B (en) 2021-01-31
RU2019131360A (ru) 2021-04-07
RU2019131360A3 (es) 2021-04-07
RU2750486C2 (ru) 2021-06-28
BR112019018469A2 (pt) 2020-04-14
JP2020514739A (ja) 2020-05-21
CO2019009796A2 (es) 2019-09-18
US11202749B2 (en) 2021-12-21
AU2017403257A1 (en) 2019-09-26

Similar Documents

Publication Publication Date Title
MY192493A (en) Urinalysis device and dry reagent for quantitative urinalysis
BR112017025051A2 (pt) ensaio celular para detecção de homodímeros anti-cd3
BR112018069849A2 (pt) kit, dispositivo e método para a detecção de câncer pancreático precoce ou de lesão precursora do câncer pancreático
WO2018187496A8 (en) PLASMA PROTEIN PROFILING FOR THE EARLY PROGNOSIS OF LUNG CANCER
MX2021006791A (es) Metodos y composiciones para detectar proteinas mal plegadas.
BR112016004963A2 (pt) biomarcadores para determinação precoce de uma resposta crítica ou de risco de vida para resposta de tratamento e/ou doença
CL2019002438A1 (es) Uso de biomarcadores en la identificación de pacientes con cáncer que serán sensibles al tratamiento con un inhibidor de prmt5.
PE20200479A1 (es) Ensayos de diagnostico para detectar, cuantificar y/o rastrear microbios y otros analitos
WO2017050939A3 (en) Method and array for diagnosing pancreatic cancer in an individual
WO2020055954A3 (en) Methods for detecting liver diseases
BR112016019740A2 (pt) monitoramento do estado de inflamação
BR112016016101A2 (pt) Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos
BR112018011224A2 (pt) processo de avaliação do risco de complicações nos pacientes que apresentam uma síndrome da resposta inflamatória sistêmica (sirs)
EA201692497A1 (ru) Биомаркеры ответа на ингибиторы ezh2
BR112018067990A2 (pt) cromogranina a como um marcador para câncer de bexiga
PE20191707A1 (es) Composicion para la medicion, prevencion o alivio del envejecimiento de la piel usando hapln1
WO2016198833A3 (en) Methods for analysing a urine sample
BR112016017901A2 (pt) ensaio inovador para detectar periostina humana
ES2845150T3 (es) Diagnóstico de pancreatitis aguda (PA) mediante la detección de glicoproteína 2 isoforma alfa (GP2A)
AR104805A1 (es) Métodos y composiciones para evaluar la capacidad de respuesta de los cánceres a los inhibidores de bet
MX2019010478A (es) Sistemas y métodos para la detección y cuantificación enzimáticas de a1c.
CO6460755A2 (es) Bioanálisis de control de calidad para productos nutricéuticos y medicinales
BR112017006569A2 (pt) composição, método para produzir uma composição, método para detectar anticorpos, uso de uma composição e kit de reagentes para a detecção de anticorpos
CO2019002599A2 (es) Biomarcadores proteicos para enfermedades asociadas con el sistema de activación por contacto
BR112019009434A2 (pt) biomarcadores para viabilidade embrionária precoce e métodos para a mesma